|
Novartis’ Troubled Lincoln Plant to Stay Sidelined Until 2013: CEO
Slow remediation of GMP problems at Novartis’ Lincoln, Neb., OTC drug plant has dashed hopes for a pre-2013 return to production, company officials say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives